New hope for Hard-to-Treat myeloma: early trial tests cevostamab in chinese patients

NCT ID NCT06934044

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Apr 24, 2026 · Updated 20 times

Summary

This early-stage trial tests a drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety and how the body processes it. Researchers will also watch for signs that the cancer shrinks or stabilizes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, 325035, China
Tianjin Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 301636, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, 430030, China

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA